Amsilarotene

DB21085InvestigationalSmall molecule

Amsilarotene is a small molecule drug. The usage of the INN stem '-arotene' in the name indicates that Amsilarotene is a arotinoid derivative. Amsilarotene is under investigation in clinical trial... Amsilarotene is under investigation in clinical trial NCT00687596 (Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy).

Mechanism: Pharmacologically active on Retinoic acid receptor beta and Retinoic acid receptor alpha
Curator reviewed
Formula / weight: C₂₀H₂₇NO₃Si₂ · 385.61 g/mol (avg)
Code names: Am-555S · TAC-101

Resolves to

Compound

UNIIQ1418F39MHCAS125973-56-0ChEMBLCHEMBL32994

Structure

InChIKeyVVTNSTLJOVCBDL-UHFFFAOYSA-NSMILESC[Si](C)(C)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C(O)=O)[Si](C)(C)C

Targets

P10826RARBP10276RARA

What you can answer from here — as of September 19, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Amsilarotene, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account